Pharmacoeconomic review report. Empagliflozin (Jardiance).

Pharmacoeconomic review report. Empagliflozin (Jardiance).

Show other versions (37)

Empagliflozin (Jardiance) is a once-daily oral antidiabetic drug belonging to the sodium glucose cotransporter-2 (SGLT-2) inhibitor class. It promotes urinary glucose excretion. This review by the CADTH Common Drug Review (CDR) will focus on the following indication: 1. For adults with type 2 diabet...

Full description

Saved in:
Bibliographic Details
Online Access: http://www.ncbi.nlm.nih.gov/books/NBK533798/
Full text
Format: Electronic eBook
Language:English
Published: Ottawa (ON) : CADTH, 2015
Series:Common drug review clinical review report.
Subjects:
Diabetes Mellitus, Type 2 > drug therapy.
Sodium-Glucose Transporter 2 Inhibitors > therapeutic use.
Sodium-Glucose Transporter 2 Inhibitors > economics.
Hypoglycemic Agents.
Cost-Benefit Analysis.
Review.
Tables.

Internet

http://www.ncbi.nlm.nih.gov/books/NBK533798/
Full text

Similar Items